The biotech reported EPS of 47 cents. Analysts were expecting 21 cents, but the number included a variety of accounting methods and so isn't strictly comparable. Sales rose 27% to $174 mil, above analyst estimates. Roughly 80% of Medicines Co.'s (MDCO) revenue came from Angiomax, an injectable anticoagulant used in patients undergoing cardiovascular surgery. The results also included $17 mil from sales of Recothrom, an agent to control surgical bleeding. Shares rose 6.2% to 35.18.